Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Mar 27, 2024 (filed on Mar 29, 2024)Insider Name:Ra Capital Management, L.P.Ownership Type:Indirect OwnershipSecurities:Pre- Funded Warrants (Right to Buy)Nature of Transaction:P - Open market or private purchase# or value acquired/disposed of:3,000,031Price:$10.00
-
Mar 27, 2024 (filed on Mar 29, 2024)Insider Name:Ra Capital Management, L.P.Ownership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:3,000,000Price:$10.00
-
Mar 27, 2024 (filed on Mar 28, 2024)Insider Name:George SimeonOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:451,659Price:$10.00
-
Mar 27, 2024 (filed on Mar 28, 2024)Insider Name:George SimeonOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:1,548,341Price:$10.00
-
Mar 04, 2024 (filed on Mar 05, 2024)Insider Name:Hastings Paul JOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:D - Disposition to issuer under Rule 16b-3(e)# or value acquired/disposed of:-137,642Price:$13.33
-
Mar 01, 2024 (filed on Mar 05, 2024)Insider Name:Hastings Paul JOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:D - Disposition to issuer under Rule 16b-3(e)# or value acquired/disposed of:-12,358Price:$13.00
-
Mar 01, 2024 (filed on Mar 05, 2024)Insider Name:Brandenberger RalphOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-2,955Price:--
-
Mar 01, 2024 (filed on Mar 05, 2024)Insider Name:Brandenberger RalphOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-3,808Price:--
-
Mar 01, 2024 (filed on Mar 05, 2024)Insider Name:Brandenberger RalphOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-8,367Price:$12.51
-
Mar 01, 2024 (filed on Mar 05, 2024)Insider Name:Brandenberger RalphOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:2,955Price:$3.89
Filings by filing date
-
Mar 27, 2024 (filed on Mar 29, 2024)Insider Name:Ra Capital Management, L.P.Ownership Type:Indirect OwnershipSecurities:Pre- Funded Warrants (Right to Buy)Nature of Transaction:P - Open market or private purchase# or value acquired/disposed of:3,000,031Price:$10.00
-
Mar 27, 2024 (filed on Mar 29, 2024)Insider Name:Ra Capital Management, L.P.Ownership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:3,000,000Price:$10.00
-
Mar 27, 2024 (filed on Mar 28, 2024)Insider Name:George SimeonOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:451,659Price:$10.00
-
Mar 27, 2024 (filed on Mar 28, 2024)Insider Name:George SimeonOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:1,548,341Price:$10.00
-
Mar 04, 2024 (filed on Mar 05, 2024)Insider Name:Hastings Paul JOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:D - Disposition to issuer under Rule 16b-3(e)# or value acquired/disposed of:-137,642Price:$13.33
-
Mar 01, 2024 (filed on Mar 05, 2024)Insider Name:Hastings Paul JOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:D - Disposition to issuer under Rule 16b-3(e)# or value acquired/disposed of:-12,358Price:$13.00
-
Mar 01, 2024 (filed on Mar 05, 2024)Insider Name:Brandenberger RalphOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-2,955Price:--
-
Mar 01, 2024 (filed on Mar 05, 2024)Insider Name:Brandenberger RalphOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-3,808Price:--
-
Mar 01, 2024 (filed on Mar 05, 2024)Insider Name:Brandenberger RalphOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-8,367Price:$12.51
-
Mar 01, 2024 (filed on Mar 05, 2024)Insider Name:Brandenberger RalphOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:2,955Price:$3.89
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 1150 Veterans Boulevard SOUTH SAN FRANCISCO CA 94080 |
Tel: | N/A |
Website: | https://www.nkartatx.com |
IR: | See website |
Key People | ||
Paul J. Hastings President, Chief Executive Officer, Director | Alyssa Levin Chief Financial and Business Officer | Ralph Brandenberger Chief Technical Officer |
James Trager Chief Scientific Officer | David Shook Chief Medical Officer | Alicia J. Hager Corporate Secretary, Chief Legal Officer |
Business Overview |
Nkarta, Inc. is a clinical-stage biopharmaceutical company advancing the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies for the treatment of patients with autoimmune diseases or hematologic malignancies. It is developing NKX019, a chimeric antigen receptor-natural killer (CAR NK) product candidate targeting the CD19 antigen and NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands. Both product candidates enable an on-demand, off-the-shelf approach involving scaled manufacturing to broaden patient access. Its NKX019 autoimmune program is based on the potential to eliminate the pathologic B cells that produce autoantibodies. Its NKX019 oncology program is based on the potential to treat a variety of B-cell malignancies by targeting the CD19 antigen that is reliably expressed on these types of cancerous cells. Its NKX101 program is designed to enhance the power of innate NK cell biology to detect and kill cancerous cells. |
Financial Overview |
For the fiscal year ended 31 December 2023, Nkarta Inc revenues was not reported. Net loss increased 3% to $117.5M. Higher net loss reflects Research and development - Balancing val increase of 6% to $88.7M (expense), General and administrative - Balancing increase of 17% to $21.6M (expense), Stock-based Compensation in R&D increase of 10% to $8M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$2.61 to -$2.40. |
Employees: | 150 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $234.03M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$121.63M as of Dec 31, 2023 |
Net annual income (TTM): | -$117.50M as of Dec 31, 2023 |
Free cash flow (TTM): | -$114.31M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 70,191,295 as of Mar 25, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |